dexpramipexole
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Dexpramipexole, a drug recently tested in patients with amyotrophic lateral sclerosis (ALS,) is able to bind F1Fo ATP synthase…
In this issue of Blood, Panch et al report that dexpramipexole reduces blood and tissue eosinophils and enables glucocorticoid…
Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders characterized by peripheral eosinophilia and eosinophil…
This phase I, open‐label, single‐dose study evaluated the pharmacokinetics, safety, and tolerability of renally excreted drug…
OBJECTIVE: To evaluate the efficacy of dexpramipexole in a Phase III study of individuals with amyotrophic lateral sclerosis (ALS…
In January the experimental drug dexpramipexole to treat amyotrophic lateral sclerosis (ALS) joined the junk heap of over 20…
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that leads to progressive weakness from loss of motor neurons…
Objective: We conducted post hoc analyses of data from a two-part, Phase II study of oral dexpramipexole to explore potential…
Dexpramipexole (KNS‐760704; [6R]‐4,5,6,7‐tetrahydro‐N6‐propyl‐2,6‐benzothiazole‐diamine) is a novel synthetic amino‐benzothiazole…